Nedometinib

DB18102InvestigationalSmall molecule

Nedometinib: Overview.

Mechanism: Pharmacologically active on Dual specificity mitogen-activated protein kinase kinase 1 and Mitogen-activated protein kinase kinase (MAPKK)
Curator reviewed
Formula / weight: C₁₇H₁₆FIN₄O₃ · 470.243 g/mol (avg)
Also known as: 2-((2-fluoro-4-iodophenyl)amino)-n-(2-hydroxyethoxy)-1-methyl-1h-pyrrolo(2,3-b)pyridine-3-carboxamide
Code names: NFX-179

Resolves to

Compound

Structure

InChIKeySENAOZROGSYRTD-UHFFFAOYSA-NSMILESCN1C(NC2=CC=C(I)C=C2F)=C(C(=O)NOCCO)C2=CC=CN=C12

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nedometinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.